Novartis Korea Ltd.
🇰🇷South Korea
Clinical Trials
2
Active:0
Completed:2
Trial Phases
1 Phases
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 3
2 (100.0%)Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration
Phase 3
Completed
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2016-04-22
- Lead Sponsor
- Novartis Korea Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT00967213
- Locations
- 🇰🇷
Dept. of Ophthalmology, KyungHee Medical Center, #1 Hoegi, Dongdaemun-gu, Seoul, Korea, Republic of
Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)
Phase 3
Completed
- Conditions
- Macular EdemaRetinal Vein Occlusion
- First Posted Date
- 2009-07-21
- Last Posted Date
- 2016-09-29
- Lead Sponsor
- Novartis Korea Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT00942864
- Locations
- 🇰🇷
Dept. of ophthalmology, Kyung Hee University Medical Center, Seoul, Korea, Republic of
News
No news found